دورية أكاديمية
A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database.
| العنوان: | A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database. |
|---|---|
| المؤلفون: | Saga Y; Medical Affairs Division, Janssen Pharmaceutical K.K, Tokyo, Japan., Chiang CL; Medical Affairs Division, Janssen Pharmaceutical K.K, Tokyo, Japan., Wakamatsu A; Medical Affairs Division, Janssen Pharmaceutical K.K, Tokyo, Japan. |
| المصدر: | Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 221-226. Date of Electronic Publication: 2023 Oct 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101719700 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2574-173X (Electronic) Linking ISSN: 2574173X NLM ISO Abbreviation: Neuropsychopharmacol Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Hoboken, NJ] : John Wiley & Sons, Inc., [2018]- |
| مواضيع طبية MeSH: | Antipsychotic Agents*/adverse effects , Tardive Dyskinesia*/chemically induced , Tardive Dyskinesia*/drug therapy , Tardive Dyskinesia*/epidemiology , Schizophrenia*/drug therapy , Drug-Related Side Effects and Adverse Reactions*/drug therapy, Humans ; Japan |
| مستخلص: | AimThe aim of this study is to summarize the spontaneous reports of tardive dyskinesia (TD) and extrapyramidal symptoms (EPSs) that occurred in Japan over the past decade. MethodsThe study analyzed TD and EPS cases reported in the Japanese Adverse Drug Event Report database between April 2011 and March 2021. The cases were stratified by the diagnoses of schizophrenia, bipolar disorders, and depressive disorders. ResultsIn total, 800 patients including a total of 171 TD cases and 682 EPS cases were reported in the JADER database across psychiatric diagnosis. The cases were caused by first-generation antipsychotics (FGA, TD: n = 105, EPS: n = 245) and second-generation antipsychotics (SGA, TD: n = 144, EPS: n = 598). The SGA were categorized based on Neuroscience-based Nomenclature (NbN) regarding pharmacological domain and mode of action, which were reported evenly as the offending agents. Among reported treatment and outcome in TD cases (n = 67, 37.6%) and EPS cases (n = 405, 59.3%), the relatively limited number of TD cases were reported as recovered/improved was also limited (n = 32, 47.8%) compared to those of EPS cases (n = 266, 65.7%). Some cases still had residual symptoms or did not recover fully (TD: n = 21, 31.3%, EPS: n = 77, 19.0%). CONCLUSION: Tardive dyskinesia and EPS have been widely reported in Japan over the past decade across psychiatric diagnoses and antipsychotic classes. LIMITATIONS: It is important to acknowledge the presence of reporting bias and the lack of comparators to accurately assess risks. Owing to the nature of spontaneous reporting, the estimation of prevalence is not feasible. (© 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.) |
| References: | Am J Psychiatry. 2004 Mar;161(3):414-25. (PMID: 14992963) Psychiatry Res. 2020 Sep;291:113249. (PMID: 32603929) Neuropsychiatr Dis Treat. 2013;9:1371-80. (PMID: 24072972) Asian J Psychiatr. 2022 Jan;67:102935. (PMID: 34844178) J Clin Psychiatry. 2004;65 Suppl 9:21-4. (PMID: 15189108) J Clin Psychiatry. 2022 Aug 3;83(5):. (PMID: 35921512) World Psychiatry. 2018 Oct;17(3):341-356. (PMID: 30192094) J Clin Psychiatry. 2000;61 Suppl 4:15-20. (PMID: 10739326) Qual Life Res. 2019 Dec;28(12):3303-3312. (PMID: 31435866) JAMA. 1991 Nov 6;266(17):2402-6. (PMID: 1681122) J Psychiatr Res. 2020 Aug;127:28-34. (PMID: 32450360) Health Technol Assess. 2017 Aug;21(43):1-218. (PMID: 28812541) Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324. (PMID: 34390232) J Clin Psychiatry. 2000;61 Suppl 4:33-8. (PMID: 10739329) Neuropsychopharmacol Rep. 2024 Mar;44(1):221-226. (PMID: 37884014) Front Psychiatry. 2022 May 17;13:823826. (PMID: 35656353) BMC Neurol. 2019 Jul 20;19(1):174. (PMID: 31325958) J Clin Psychopharmacol. 2010 Oct;30(5):531-40. (PMID: 20814320) Acta Psychiatr Scand. 1997 Sep;96(3):206-16. (PMID: 9296552) Schizophr Res. 2005 Dec 1;80(1):33-43. (PMID: 16171976) Acta Psychiatr Scand. 1996 Aug;94(2):118-24. (PMID: 8883573) Int J Geriatr Psychiatry. 2014 Apr;29(4):359-66. (PMID: 23939789) World Psychiatry. 2018 Oct;17(3):330-340. (PMID: 30192088) J Psychopharmacol. 2010 Jul;24(7):1031-5. (PMID: 19487321) Am J Psychiatry. 2006 Aug;163(8):1438-40. (PMID: 16877660) Tremor Other Hyperkinet Mov (N Y). 2014 Oct 23;4:266. (PMID: 25374768) |
| معلومات مُعتمدة: | Janssen Pharmaceutical K.K. |
| فهرسة مساهمة: | Keywords: JADER; antipsychotic; extrapyramidal symptoms; pharmacovigilance; tardive dyskinesia |
| المشرفين على المادة: | 0 (Antipsychotic Agents) |
| تواريخ الأحداث: | Date Created: 20231026 Date Completed: 20240314 Latest Revision: 20240315 |
| رمز التحديث: | 20240315 |
| مُعرف محوري في PubMed: | PMC10932779 |
| DOI: | 10.1002/npr2.12385 |
| PMID: | 37884014 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2574-173X |
|---|---|
| DOI: | 10.1002/npr2.12385 |